ESMO: European Society for Medical Oncology

1. A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is Associated with Immunotherapy Response

   New measure of tumour mutational burden based on genomic regions unlikely to undergo loss

2. Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients with BRAF V600E-mutated Colorectal Cancer

   Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition

3. FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC

   Evidence for efficacy is based on the results from the KEYNOTE-091 study

4. Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint Inhibitors in the Treatment of Advanced NSCLC, Particularly Among the Older Patients

   Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age

5. EMA Recommends Extension of Indications for Darolutamide

   New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy